EUVIMEDEUVIMED entdecken
Crossref

Hypoxia‐inducible factor‐targeting therapy augmented the sensitivity to programmed death ligand‐1 blockade by enhancing interferon‐γ‐induced chemokines in tumor cells

Yohei Yabuki, Atsushi Mitsuhashi iD, Hirokazu Ogino, Aito Yoshida, Na Thi Nguyen, Hiroto Yoneda, Ryohiko Ozaki, Yuki Tsukazaki, Yutaka Morita, Hiroshi Nokihara, Seidai Sato, Tsutomu Shinohara und 2 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35301 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Yohei Yabuki und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan. Hauptthemen laut MEDLINE: B7-H1 Antigen, Interferon-gamma, Chemokine CXCL10, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Japan Science and Technology Agency (JST), Taiho Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) targeting programmed death ligand‐1 (PD‐L1) provide clinical benefits for various advanced malignancies. However, the predictive factors that determine sensitivity to ICIs have not been fully elucidated. We focused on tumor‐derived CXCL10/11 as a pivotal factor that determines the response to PD‐L1 blockade by regulating T cell accumulation and tumor angiogenesis. We previously reported that CXCL10/11 was upregulated by interferon (IFN)‐γ in ICI‐sensitive tumor cells but not in ICI‐resistant cells, including mouse Lewis lung carcinoma (LLC). In the present study, gene silencing of tumor‐derived CXCL10/11 induced resistance to PD‐L1 blockade in AB1‐HA mesothelioma cell‐bearing mice. To identify the mechanisms underlying ICI resistance, we performed a microarray analysis to compare the IFN‐γ‐inducible genes between ICI‐sensitive AB1‐HA and ICI‐resistant LLC in vitro. A pathway analysis based on microarray data indicated that hypoxia‐inducible factor (HIF) 1A is the key signal that inhibits CXCL10/11 expression. We revealed that the HIF1A inhibitors echinomycin (EC) and YC‐1 upregulated CXCL10/11 genes induced by IFN‐γ in tumor cells in vitro. In addition, combination therapy with PD‐L1 blockade and EC demonstrated synergistic antitumor effects in LLC‐bearing mice. Combination therapy enhanced tumor infiltration of CD8 T cells and suppressed tumor angiogenesis. The present study suggests that HIF1A signaling in tumor cells dominates ICI resistance via the downregulation of tumor‐derived CXCL10/11.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenInterferon-gammaChemokine CXCL10Immune Checkpoint InhibitorsCarcinoma, Lewis LungHypoxia-Inducible Factor 1, alpha SubunitAnimalsMiceCell Line, TumorHumansDrug Resistance, NeoplasmMice, Inbred C57BLGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

CXCL10/11HIF1Aangiogenesisimmune checkpoint inhibitorinterferon‐γ

Substanzen

B7-H1 AntigenInterferon-gammaChemokine CXCL10Immune Checkpoint InhibitorsHypoxia-Inducible Factor 1, alpha SubunitCxcl10 protein, mouseCd274 protein, mouseHif1a protein, mouse

Autor:innen und Institutionen

  • Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
  • Department of Community Medicine for Respirology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
  • Department of Community Medicine for Respirology, Hematology and Metabolism, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
  • Department of Community Medicine for Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.

ORCID-Profile: Atsushi Mitsuhashi

Förderung

  • Japan Society for the Promotion of Science
  • Japan Science and Technology Agency (JST)
  • Taiho Pharmaceutical

Zitieren

APA

Yabuki, Y., Mitsuhashi, A., Ogino, H., Yoshida, A., Nguyen, N. T., Yoneda, H., Ozaki, R., Tsukazaki, Y., Morita, Y., Nokihara, H., Sato, S., Shinohara, T., Hanibuchi, M., & Nishioka, Y. (2025). Hypoxia‐inducible factor‐targeting therapy augmented the sensitivity to programmed death ligand‐1 blockade by enhancing interferon‐γ‐induced chemokines in tumor cells. International Journal of Cancer. https://doi.org/10.1002/ijc.35301

Vancouver

Yabuki Y, Mitsuhashi A, Ogino H, Yoshida A, Nguyen NT, Yoneda H, et al. Hypoxia‐inducible factor‐targeting therapy augmented the sensitivity to programmed death ligand‐1 blockade by enhancing interferon‐γ‐induced chemokines in tumor cells. International Journal of Cancer. 2025. doi:10.1002/ijc.35301

BibTeX
@article{Yabuki2025,
  author = {Yabuki, Yohei and Mitsuhashi, Atsushi and Ogino, Hirokazu and Yoshida, Aito and Nguyen, Na Thi and Yoneda, Hiroto and Ozaki, Ryohiko and Tsukazaki, Yuki and Morita, Yutaka and Nokihara, Hiroshi and Sato, Seidai and Shinohara, Tsutomu and Hanibuchi, Masaki and Nishioka, Yasuhiko},
  title = {Hypoxia‐inducible factor‐targeting therapy augmented the sensitivity to programmed death ligand‐1 blockade by enhancing interferon‐γ‐induced chemokines in tumor cells},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35301}
}
Kostenlos starten →